1
Lisa C McConlogue, Jun Zhao: Transgenic animals harboring APP allele having swedish mutation. Athena Neurosciences, Eli Lilly and Company, Townsend and Townsend and Crew, March 18, 1997: US05612486 (124 worldwide citation)


The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.


2
Lisa C McConlogue, Dale B Schenk, Peter A Seubert, Sukanto Sinha, Jun Zhao: Methods of screening for .beta.-amyloid peptide production inhibitors. Athena Neurosciences, Townsend and Townsend and Crew, February 18, 1997: US05604102 (72 worldwide citation)


Processing of .beta.-amyloid precursor protein (.beta.APP) is monitored by detecting the secretion of a soluble amino-terminal fragment or .beta.APP (ATF-.beta.APP) resulting from cleavage of .beta.APP at the amino-terminus of .beta.-amyloid peptide. Secretion of ATF-.beta.APP in animal models may b ...


3
Lisa C McConlogue, Kate D Games, Theodore A Yednock, Tan Hua, Elizabeth Messersmith, Frederique Bard: Selecting compounds to reduce inflammation associated with Alzheimer's disease. Elan Pharmaceuticals, Townsend and Townsend and Crew, December 16, 2003: US06664442 (17 worldwide citation)


The invention includes identification of specific markers, the elevation of which in central nervous tissue is associated with Alzheimer's Disease. The invention also includes improved assay methods for selecting compounds useful in reducing or preventing onset of the pathology associated with ...


4
Kate Dora Games, Dale B Schenk, Lisa C McConlogue, Peter A Seubert, Russell E Rydel: Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimers disease FAD DNA sequence. Elan Pharmaceuticals, Townsend and Townsend and Crew, March 6, 2007: US07186881 (10 worldwide citation)


The construction of transgenic animal models of human Alzheimer's disease, and methods of using the models to screen potential Alzhe## disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all t ...


5
Lisa C McConlogue, Jun Zhao, Sukanto Sinha: Monitoring APP cleavage in transgenic rodents comprising an APP-Swedish mutation. Elan Pharmaceuticals, Eli Lilly and Company, Townsend and Townsend and Crew, February 20, 2007: US07179953


The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.


6
Lisa C McConlogue, Jun Zhao, Sukanto Sinha: Monitoring APP cleavage in transgenic rodents comprising an APP Swedish mutation. Elan Pharmaceuticals, Eli Lilly and Company, Townsend and Townsend and Crew, October 27, 2009: US07608749


The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.


7
Lisa C McConlogue, Elizabeth Messersmith, Frederique Bard: Screening markers and methods for neurodegenerative disorders. Elan Pharmaceuticals, Townsend And Townsend And Crew, October 28, 2004: US20040213739-A1


The invention includes identification of specific markers, the elevation of which in central nervous tissue is associated with Alzheimer's Disease. The invention also includes improved assay methods for selecting compounds useful in reducing or preventing onset of the pathology associated with Alzhe ...


8
Lisa C McConlogue, Jun Zhao, Sukanto Sinha: Transgenic animals harboring appallele having swedish mutation. Elan Pharmaceuticals, Eli Lilly and Company, Townsend And Townsend And Crew, January 27, 2005: US20050022257-A1


The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.


9
Lisa C McConlogue, Jun Zhao, Sukanto Sinha, Dale B Schenk: Monitoring APP cleavage in transgenic rodents comprising an APP swedish mutation. Elan Pharmaceuticals, Eli Lilly and Company, Townsend And Townsend And Crew, August 23, 2007: US20070199079-A1


The invention provides transgenic non-human animals and transgenic non-human mammalian cells harboring a transgene encoding an APP polypeptide comprising the Swedish mutation.


10
Lisa C McConlogue, Kate D Games, Theodore A Yednock, Tan Hua, Elizabeth Messersmith, Frederique Bard: Screening markers and methods for neurodegenerative disorders. Elan Pharmaceuticals, October 10, 2002: US20020147998-A1


The invention includes identification of specific markers, the elevation of which in central nervous tissue is associated with Alzheimer's Disease. The invention also includes improved assay methods for selecting compounds useful in reducing or preventing onset of the pathology associated with Alzhe ...



Click the thumbnails below to visualize the patent trend.